In palbociclib-resistant KRAS-mutant NSCLC cells, ERK-dependent (but not AKT-dependent) phosphorylation of TSC2 blocked its ability to negatively regulate the mTOR pathway, resulting in mTOR activation. Here, KRAS is linked to non-small cell lung carcinoma.